Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies.

IF 2.4 4区 医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2023-10-01 Epub Date: 2023-10-05 DOI:10.2217/rme-2023-0118
Leigh Turner, Juan Ramon Martinez, Shemms Najjar, Thevin Rajapaksha Arachchilage, Victoria Sahrai, Jia Chieng Wang
{"title":"Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies.","authors":"Leigh Turner, Juan Ramon Martinez, Shemms Najjar, Thevin Rajapaksha Arachchilage, Victoria Sahrai, Jia Chieng Wang","doi":"10.2217/rme-2023-0118","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Examining websites of US businesses engaged in direct-to-consumer advertising of putative stem cell treatments and exosome therapies, this study investigated the marketing claims such companies make about the purported safety and efficacy of these products. <b>Methods:</b> Data mining and content analysis of company websites were used to identify and analyze safety and efficacy claims. <b>Results:</b> Of the 978 businesses analyzed, less than half the companies made identifiable claims about the safety and efficacy of their advertised stem cell and exosome products. We also explored how companies framed the stem cell and exosome products they promoted. Representations ranged from assertions that such products are unproven and investigational to claims they constituted cures. Most advertising frames fell between these poles. <b>Conclusion:</b> Some businesses include in their marketing representations claims about the safety and efficacy of advertised products. Businesses that did not make such assertions use other techniques to attract prospective clients.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.2217/rme-2023-0118","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/5 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Examining websites of US businesses engaged in direct-to-consumer advertising of putative stem cell treatments and exosome therapies, this study investigated the marketing claims such companies make about the purported safety and efficacy of these products. Methods: Data mining and content analysis of company websites were used to identify and analyze safety and efficacy claims. Results: Of the 978 businesses analyzed, less than half the companies made identifiable claims about the safety and efficacy of their advertised stem cell and exosome products. We also explored how companies framed the stem cell and exosome products they promoted. Representations ranged from assertions that such products are unproven and investigational to claims they constituted cures. Most advertising frames fell between these poles. Conclusion: Some businesses include in their marketing representations claims about the safety and efficacy of advertised products. Businesses that did not make such assertions use other techniques to attract prospective clients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
营销所谓干细胞治疗和外泌体治疗的美国企业提出的安全性和有效性声明。
目的:本研究调查了从事假定干细胞治疗和外泌体治疗的直接面向消费者广告的美国企业的网站,调查了这些公司对这些产品的所谓安全性和有效性的营销声明。方法:采用数据挖掘和内容分析的方法对公司网站的安全性和有效性声明进行识别和分析。结果:在分析的978家企业中,只有不到一半的公司对其广告中的干细胞和外泌体产品的安全性和有效性提出了可识别的声明。我们还探讨了公司如何构建他们推广的干细胞和外泌体产品。陈述的范围从声称这些产品未经证实和研究到声称它们构成了治疗方法。大多数广告架都落在这两根杆子之间。结论:一些企业在其营销陈述中包含了关于广告产品安全性和有效性的声明。没有做出这种断言的企业使用其他技术来吸引潜在客户。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Regenerative medicine
Regenerative medicine 医学-工程:生物医学
CiteScore
4.20
自引率
3.70%
发文量
82
审稿时长
6-12 weeks
期刊介绍: Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.
期刊最新文献
Industry updates from the field of stem cell research and regenerative medicine in August 2024. Ultrasound-guided injection using leucocyte-rich platelet-rich plasma for treatment of meniscal injuries in a duathlete: a case report. Influencing factors and repair advancements in rodent models of peripheral nerve regeneration. Extracellular vesicles for corneal regeneration: the new frontier. Industry updates from the field of stem cell research and regenerative medicine in July 2024.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1